Goldman Sachs’s Array Biopharma Inc ARRY Stock Holding History

Goldman Sachs’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-650,000	Closed	-$15.8M	–	5494
2019 Q1	$15.8M	Buy	+650,000	New	+$13.5M	﹤0.01%	2065
2015 Q4	–	Sell	-67,500	Closed	-$308K	–	7486
2015 Q3	$308K	Sell	67,500 -7,500	-10%	-$44.5K	﹤0.01%	5591
2015 Q2	$541K	Buy	+75,000	New	+$553K	﹤0.01%	5116
2015 Q1	–	Sell	-80,000	Closed	-$378K	–	7395
2014 Q4	$378K	Buy	80,000 +600	+0.8%	+$2.37K	﹤0.01%	5551
2014 Q3	$283K	Sell	79,400 -600	-0.8%	-$2.37K	﹤0.01%	5810
2014 Q2	$365K	Buy	+80,000	New	+$331K	﹤0.01%	5604
2013 Q3	–	Sell	-80,000	Closed	-$363K	–	6777
2013 Q2	$363K	Buy	+80,000	New	+$430K	﹤0.01%	5195

Other funds holding ARRY

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Goldman Sachs's ARRY Position: Q3 2019 in Review

Goldman Sachs sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 4,025,690 shares — an estimated $187M sold.

Goldman Sachs first reported a position in ARRY in Q2 2013 and held it in 25 quarters. The position peaked at $187M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

Goldman Sachs reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
Goldman Sachs sold 4,025,690 Array Biopharma Inc shares in Q3 2019, an estimated $187M.
Goldman Sachs first reported a position in Array Biopharma Inc in Q2 2013 and held it in 25 quarters.
Goldman Sachs's Array Biopharma Inc position peaked at $187M in Q2 2019.
1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Goldman Sachs's 13F filing for Q3 2019, filed 14 Nov 2019.